Adobe [ADBE]
As of 2026-07-29 · spot $263.445 · This memo issues no position verdict. What follows establishes what is investable and at what size.
This is the first cluster tonight in which an options vehicle is actually available. Nine of the ten names where the chain was pulled before this cluster could not be filled at any size:
| Name | Chain depth found | Verdict |
|---|---|---|
| GMED | 13 contracts | Uninvestable |
| HCA | 18 — maximum open interest across an entire March-2027 expiry | Uninvestable |
| CRDO | 78 | Uninvestable |
| ISSC | 506 | Uninvestable |
| KNSA | 2,598 total across the chain | Marginal |
| ADBE | 3,356 at a single strike, 59 contracts in the scanned window | Investable |
| CRM / WDAY / PANW / CRWD | 4,229 / 6,771 / 2,713 / 5,883 at a single strike | Investable |
The Liquidity Criteria exists because "a vehicle that cannot be filled is not a vehicle." The correct response to passing it is to quantify the pass. On ADBE the pass is genuine but it is the thinnest quoted of the five, and the bid/ask is materially wider than CRM's — which matters, because Adobe is the name where the analysis most supports taking risk.
| Metric | Value | Basis |
|---|---|---|
| 3-month average daily volume | 6,285,636 shares | 62 sessions to 2026-07-28 |
| 3-month average daily value | $1,656m | VWAP-weighted |
| 252-day volatility | 37.7% | the lowest of the five names in this cluster |
| Option-implied volatility, Jan-27 | ~51–56% | §3 |
Sizing implication. At 20% of ADV, ~$331m can be transacted in a session. Liquidity constrains nothing for this book.
Note the vol gap: 37.7% realised against 51–56% implied. A ~15-point spread. Options are expensive relative to Adobe's own realised volatility, which argues for the equity rather than the call as the vehicle, and argues against buying vega here. This is worth stating because ADBE has the best implied-path margin in the cluster and the instinct is to reach for leverage.
Liquidity Criteria: PASS.
Scanned: calls, expiry 2026-11-01 to 2027-02-28, strikes $224–$329 (0.85× to 1.25× spot). 59 contracts returned. Snapshots are live quotes and Greeks from the Alpaca options entitlement.
| Contract | Expiry | Strike | Open interest | Bid | Ask | Spread | Bid size | Ask size | IV | Delta |
|---|---|---|---|---|---|---|---|---|---|---|
| ADBE270115C00300000 | 2027-01-15 | 300 | 3,356 | 23.37 | 25.98 | 10.6% | 275 | 285 | 52.6% | 0.434 |
| ADBE261218C00260000 | 2026-12-18 | 260 | 2,979 | 35.93 | 38.37 | 6.6% | 177 | 49 | 54.8% | 0.586 |
| ADBE261218C00250000 | 2026-12-18 | 250 | 2,076 | 39.86 | 45.11 | 12.4% | 333 | 199 | 55.9% | 0.630 |
| ADBE270115C00270000 | 2027-01-15 | 270 | 1,644 | 32.59 | 37.81 | 14.8% | 429 | 321 | 52.8% | 0.551 |
| ADBE270115C00320000 | 2027-01-15 | 320 | 1,369 | 16.72 | 20.10 | 18.4% | 399 | 177 | 51.2% | 0.357 |
| ADBE270115C00240000 | 2027-01-15 | 240 | 1,182 | 48.42 | 52.50 | 8.1% | 410 | 244 | 55.0% | 0.674 |
Reference contract: ADBE270115C00300000 — 3,356 open interest, 275×285 quoted size, delta 0.434. At the $25.98 offer that is ~$740k of immediately available offer, three orders of magnitude beyond what HCA or GMED could absorb.
But read the spreads before congratulating the chain. ADBE's bid/asks run 6.6% to 18.4%, against CRM's 4.4% at its reference strike. The $270 and $320 strikes quote 14.8% and 18.4% wide despite carrying 400+ contracts of size. Quoted size is deep; quoted price is not tight. Any structure here must be worked, and paying the offer on a two-leg spread costs 15–20% of the premium before the thesis has done anything.
Structures that are actually fillable: - Outright Jan-27 $300 call — 3,356 OI, tightest spread of the far-dated strikes at 10.6%, delta 0.434. - Dec-18-2026 $260 call — 2,979 OI, 6.6% spread, delta 0.586. The tightest quote on the chain, and it captures both the Q3 FY26 print (~mid-Sep) and the Q4 print with FY27 guidance (~mid-Dec) if the expiry falls after it. Note IV 54.8% versus 52.6% for Jan-27: a 2.2-point term premium for the December event risk. - Jan-27 $270/$320 call spread — both legs quoted with 177–429 contracts of size, OI 1,644 and 1,369. Net debit ~$16.5 mid. Defined risk, but a combined ~33% of round-trip spread cost across the two legs makes this the worst-value structure on the chain despite being the most conservative-looking. - Cash equity — $1,656m ADV, 37.7% realised vol against 51–56% implied. On the numbers this is the better vehicle, and the memo says so rather than reaching for the derivative because one is available.
Boundaries of the pull: strikes outside $224–$329 and expiries outside Nov-2026 to Feb-2027 were not scanned, and I make no claim about their depth. Puts were not pulled — this is a long-only book and no hedge structure is proposed.
Parameters, not a recommendation.
Vehicle. The equity. Three reasons, all quantified above: (i) realised vol 37.7% against implied 51–56%, so options are ~15 points rich; (ii) chain spreads of 6.6–18.4% versus CRM's 4.4%; (iii) the thesis is a five-year implied-path cushion of +9.3pp, not a dated catalyst — and a multi-year re-rating thesis expressed in a five-month option is a mismatch of instrument to horizon, which is the same error valuation.md documents in the 5-year-DCF-to-12-month-target attempt.
If a defined-risk expression is nonetheless required, the Dec-18 $260 call is the only strike on this chain where the quote is tight enough (6.6%) to justify paying it, and it sits on the Q4/FY27-guidance catalyst.
Entry. No trigger is defended. Momentum is weak — Adobe is −45.7% over five years and sits at the 10th percentile of its own P/S range — and Momentum Criteria is MEASURED: it governs when, never whether. A book wanting confirmation should wait for the first FY2027 ending-ARR growth guide (~mid-Dec 2026), which is the single number that resolves the organic-ARR question in Research §2.
Sizing. Inverse-volatility. At 37.7% realised, ADBE takes the largest weight of the five names in this cluster. That the best implied-path margin and the lowest volatility coincide is a property of this cluster, not a rule — but it means the sizing mechanism and the ranking do not fight each other here, which is unusual and worth noting.
Invalidation. Three hard, dated, falsifiable tests: 1. FY2027 guided ending-ARR growth below 9% including acquisitions — i.e. organic below ~7.5%. This is the direct test of Research §2 and it arrives ~mid-Dec 2026. 2. RPO declining year over year. RPO grew ~1% against revenue up 12.7%; a decline would confirm that the contracted base is shrinking while recognised revenue coasts. 3. A third consecutive quarter of operating-margin compression. Two are on the board (Q2 FY26 at 33.8% reported / 34.8% ex-impairment against 35.9%). A third breaks the 36% terminal-margin assumption that the +9.3pp margin rests on.
What does not constitute invalidation: - A goodwill impairment. Q2 already carried $68m in Publishing & Advertising, and "impairment" appears 25 times in each of the last two 10-Ks. These are non-cash marks on legacy assets and they say nothing about Creative Cloud. - A GAAP EPS miss driven by FX. Adobe reported 13% growth and 11% constant currency in the same quarter; the 2pp wedge will reverse and it is not a business event. - The permanent CFO hire, whoever it is. It is a monitorable on disclosure posture (Research §8), not a thesis input.